Is NCT06780137 recruiting in Nashville, TN?

Yes, NCT06780137 is currently recruiting participants at its Nashville, TN location. This small cell lung cancer clinical trial is actively enrolling qualified participants.

How do I join the small cell lung cancer clinical trial in Nashville?

To join this clinical trial in Nashville, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Nashville clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Small Cell Lung Cancer Clinical Trial in Nashville, TN

About This Small Cell Lung Cancer Study in Nashville

Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory. Gocatamig is a new type of immunotherapy that uses a person's immune system to find and destroy cancer cells. Ifinatamab deruxtecan (also known as I-DXd) is a drug which binds to a specific target on cancer cells and delivers treatment to destroy those cells. Durvalumab is a different type of immunotherapy that also destroys cancer cells. Researchers want to

Sponsor: Merck Sharp & Dohme LLC

Who Can Participate

Inclusion Criteria

Has histologically or cytologically confirmed SCLC that is extensive stage (defined as Stage IV (T any, N any, M1a/b/c) following at least 1 prior line of systemic therapy that included platinum-based chemotherapy

Must be able to provide archival tumor tissue sample or fresh biopsy tissue sample

Human immunodeficiency virus (HIV) infected participants must have well controlled HIV on antiretroviral therapy (ART)

Exclusion Criteria

Pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedure

Any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use except for a history of radiation pneumonitis that did not require steroids

Current history of ILD or clinical or radiographic suspicion of ILD for which the diagnosis of ILD cannot be ruled out

Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses

Active or history of immune deficiency with the exception of HIV-infected participants with well controlled HIV on ART

History within 6 months before the first dose of study intervention of coronary/peripheral artery bypass graft and/or any coronary/peripheral angioplasty or clinically significant cardiovascular disease such as myocardial infarction, symptomatic congestive heart failure (CHF) (New York Heart Association \> class II), and/or uncontrolled cardiac arrhythmia

History of arterial thrombosis (eg, stroke or transient ischemic attack) within 6 months before the first dose of study intervention

Active clinically significant infection requiring systemic therapy

History of allogeneic tissue/solid organ transplant

History of leptomeningeal disease

Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids

Receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of chronic immunosuppressive therapy within 7 days prior to the first dose of study intervention

Known additional malignancy that is progressing or has required active treatment within the past 3 years

Untreated or symptomatic brain metastases

Active viral hepatitis, defined as hepatitis A (hepatitis A virus immunoglobulin M \[IgM\] positive in the setting of associated signs/symptoms), hepatitis B (hepatitis B virus surface antigen \[HbsAg\] positive and/or detectable hepatitis B virus \[HBV\] deoxyribonucleic acid \[DNA\]), or hepatitis C (hepatitis C virus \[HCV\] antibody positive and detectable HCV ribonucleic acid). Participants with HBV with undetectable viral load after treatment are eligible. Participants with HCV with undetectable virus after treatment are eligible.

Part 1 only: Radiation therapy to the lung \>30 Gy within 6 months before the start of study intervention

Part 1 only: Abdominal radiation within 4 weeks before start of study intervention

Part 1 only: Anticancer hormonal treatment (except luteinizing hormone-releasing hormone \[LHRH\]) within 2 weeks before start of study intervention

Part 1 only: Systemic anticancer therapy (except antibody-based anticancer therapy) or investigational agents within 3 weeks or 5 half-lives, whichever is longer

Part 1 only: Antibody-based cancer therapy within 3 weeks before start of study intervention

Part 1 only: Chloroquine/hydroxychloroquine within 2 weeks before start of study intervention

Part 1 only: Clinically significant corneal disease

Part 1 only: Has other uncontrolled or significant protocol-specified cardiovascular disease

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Nashville?

Yes, this clinical trial (NCT06780137) has an active research site in Nashville, TN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Small Cell Lung Cancer Treatment Options in Nashville, TN

If you're searching for small cell lung cancer treatment options in Nashville, TN, this clinical trial (NCT06780137) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Nashville research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced small cell lung cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all small cell lung cancer clinical trials near you to find additional studies recruiting in your area.

Small Cell Lung Cancer Clinical Trial in Nashville, TN

Expert Care in Nashville

IRB Approved

No-Cost Care

Apply for This Nashville Location

Why Participate?

Simple Process